SCHEMBL857552

SCHEMBL857552

FC(F)(F)c1cccc2[c]ncnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.38
TAAR1 Q96RJ0 1/20 0.35
NR1H2 P55055 4/20 0.33
NR1H3 Q13133 4/20 0.33
NCF1 P14598 1/20 0.33
ESR1 P03372 1/20 0.33
CYP3A4 P08684 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HSD11B1 P28845 2/20 0.32
AXL P30530 1/20 0.32
MRGPRX1 Q96LB2 1/20 0.31
GRM2 Q14416 1/20 0.31
P2RX7 Q99572 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856106 0.76 PARP1 (0.33) PARP1TAAR1ALDH1A1CYP1A2HSD17B10
SCHEMBL855665 0.71 NQO2 (0.41) CYP3A4ALDH1A1
SCHEMBL849098 0.71 NCF1 (0.38) PARP1TAAR1NR1H2NR1H3NCF1
SCHEMBL2454281 0.68 PARP1 (0.49) PARP1NR1H2NR1H3NCF1ESR1
SCHEMBL15200655 0.68 HTT (0.32) ALDH1A1GRM2
SCHEMBL21348441 0.66 PARP1 (0.50) PARP1NR1H2NR1H3NCF1ESR1
SCHEMBL3631984 0.66 CYP3A4 (0.50) PARP1ESR1CYP3A4ALDH1A1CYP1A2
SCHEMBL862075 0.65 IDO1 (0.38) CYP3A4ALDH1A1CYP1A2CYP2D6ALOX15
SCHEMBL29829936 0.64 PARP1 (0.49) PARP1NR1H2NR1H3NCF1ALDH1A1
SCHEMBL29416463 0.64 PARP1 (0.49) PARP1NR1H2NR1H3NCF1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PARP1 2347/4885TAAR1 4259/4885NR1H2 1458/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PARP1 2511/4885TAAR1 4280/4885NR1H2 1399/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PARP1 2250/4885TAAR1 4176/4885NR1H2 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.